{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.256","value":"0.09"},{"groupId":"OG001","spread":"0.253","value":"-0.81"},{"groupId":"OG002","spread":"0.271","value":"-0.60"}]}],"title":"Change from Baseline at Week 1 [N=63; 64; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.284","value":"-0.11"},{"groupId":"OG001","spread":"0.281","value":"-1.13"},{"groupId":"OG002","spread":"0.298","value":"-0.95"}]}],"title":"Change from Baseline at Week 4 [N=63; 64; 58]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.288","value":"-0.35"},{"groupId":"OG001","spread":"0.285","value":"-1.43"},{"groupId":"OG002","spread":"0.302","value":"-0.98"}]}],"title":"Change from Baseline at Week 8 [N=62; 63; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.295","value":"-0.33"},{"groupId":"OG001","spread":"0.292","value":"-1.65"},{"groupId":"OG002","spread":"0.320","value":"-0.90"}]}],"title":"Change from Baseline at Week 12 [N=62; 63; 54]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.290","value":"-0.33"},{"groupId":"OG001","spread":"0.287","value":"-1.60"},{"groupId":"OG002","spread":"0.304","value":"-0.93"}]}],"title":"Change from Baseline at EOT [N=63; 64; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"For each micturition and/or incontinence episode in the 3 days preceding the clinic visit, participants rated the degree of associated urgency (the sudden compelling desire to pass urine, which is difficult to defer) according to the following scale: 0: No Urgency, felt no need to empty my bladder but did so for another reason; 1: Mild Urgency, could postpone passing water for as long as necessary; 2: Moderate Urgency, could postpone passing water for a short while; 3: Severe Urgency, could not postpone passing water; 4: Urge Incontinence, leaked before reaching the toilet.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 1, 4, 8 and 12","title":"Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Urgency Episodes With Urgency Severity ≥ 3 Per 24 Hours","type":"SECONDARY","unitOfMeasure":"Urgency episodes"}